Results 51 to 60 of about 923 (130)

Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China [PDF]

Frontiers in Pharmacology
Introduction: Numerous studies have explored the treatment outcomes of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19. However, direct comparisons between these two drugs are still relatively limited.
Nan Shang, Xianlin Li, Zhiyu Guo, Lan Zhang, Shanshan Wang   +4 more
doaj   +2 more sources

Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis

PLOS ONE
Objective The aim of this study was to assess the effectiveness and safety of azvudine in treating coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2).
Bahman Amani, Behnam Amani
semanticscholar   +3 more sources

Validation study for assessing COVID-19 pneumonia treatments [PDF]

Scientific Reports
This study investigates the effectiveness of Azvudine and nirmatrelvir-ritonavir (Paxlovid) in treating COVID-19 pneumonia through an analysis of real-world clinical data.
Kaibin Lin, Bing Zhou, Yi Wu, Zheng Wang, Shu Li, Yuanyuan Li, Fen Li, Yang Xue, Zirou Liu, Jiafen Liao   +9 more
doaj   +2 more sources

A Real-World Retrospective Study on the Efficacy and Safety of Four Antiviral Drugs for Hospitalized COVID-19 Patients: Nirmatrelvir/Ritonavir, Simnotrelvir/Ritonavir, Molnupiravir and Azvudine [PDF]

Infection and Drug Resistance
Ximiao Yu,1,* Ruiqi Luo,2,* Guijuan Xie,2 Jiali Ji,3,4 Jiehong Wang,1 Xiyue Li,3 Xiaojun Qian,2 Xun Wang1,2,5 1Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu Province, People’s Republic of China; 2Department of Pulmonary and Critical
Yu X, Luo R, Xie G, Ji J, Wang J, Li X, Qian X, Wang X   +7 more
doaj   +2 more sources

Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities [PDF]

Journal of Infection, 2023
Yating Dian, Yu Meng, Yuming Sun, Guangtong Deng, Furong Zeng   +4 more
openalex   +3 more sources

Inflammatory predictors (eosinophil, C-RP and IL-6) and effectiveness of oral Azvudine tablets treatment in COVID-19 hospitalized patients: A retrospective, self-controlled study

Heliyon, 2023
Background: Although vaccinations and antiviral drugs are widely used in the clinical treatment worldwide, there is little investigation on the clinical outcomes and effectiveness of oral Azvudine tablets (FNC) treatment in COVID-19 hospitalized patients.
Yanli Zhao, Gan Gao, Wenhui Li, Zuqing Xu, Xiao Wang, Rong Chang   +5 more
doaj   +1 more source

Cover Picture: Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study (View 2/2025) [PDF]

VIEW, Volume 6, Issue 2, April 2025.
In the cohort of SARS‐CoV‐2 infected patients with pre‐existing chronic respiratory diseases, azvudine can not only relieve disease symptoms by blocking the activity of the viral RNA polymeraseand inhibiting viral replication, but also perform immune‐enhancing effect by increasing the number and function of serum lymphocytes, and thus activating the ...
Junyi Sun, Mengzhao Yang, Daoke Yao, Yongjian Zhou, Xiaobo Hu, Guowu Qian, Yiqiang Yuan, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Yanyang Zhang, Xinjun Hu, Zujiang Yu, Guangying Cui, Zhigang Ren   +17 more
openalex   +2 more sources

Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials

Frontiers in Pharmacology, 2023
Azvudine (FNC) is a synthetic nucleoside analog used to treat adult patients living with human immunodeficiency virus-1 (HIV-1) infection with high viral load.
Ke-Wei Zhu
doaj   +1 more source

Azvudine therapy of common COVID‐19 in hemodialysis patients

Journal of Medical Virology, 2023
AbstractThere is no antiviral study on hemodialysis patients infected with coronavirus disease 2019 (COVID‐19), especially on the application of 2′‐deoxy‐2′‐β ‐fluoro‐4′‐azidocytidine (Azvudine, FNC) antiviral therapy. We conducted a multicenter observational study involving 1008 hemodialysis patients.
Shunlai Shang, Bo Fu, Yanqiu Geng, Jian Zhang, Dawei Zhang, Fenglin Xiao, Zhaojun Sheng, Jingbo Zhai, Wenge Li, Xiangmei Chen, Chunfu Zheng, Qinggang Li   +11 more
openaire   +2 more sources

Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID-19: A Propensity Score-Matched Analysis. [PDF]

Infect Drug Resist
Zhang S, Tan S, Yang B, Wu Y, Yuan G, Chen F, Liu L.   +6 more
europepmc   +2 more sources